Abstract:Objective To clarify the actions of somatostatin （SST） on the hepatic fibrogenesis in experimental rats. Methods Seventy five Sprague-Dawley rats were divided into 5 groups at random, including normal control, model control, SST-treated model groups of high, medium and low doses （200 μg·kg-1·d-1, 100 μg·kg-1·d-1 and 50 μg·kg-1·d-1, respectively）（n=15, in each group）. All rats, except for the normal controls, were injected with 40% carbon tetrachloride （CCl4） subcutaneously for 8 weeks to establish hepatic fibrosis. Meanwhile, rats of SST-treated model groups were given different doses of SST twice a day in the same way. Then the liver function, serum levels of hyaluronic acid （HA）, laminin （LM）, and collagen type IV （CIV） were tested. The collagen types I and III, and pathological changes in liver tissue were assessed. Results Being compared with the model control group, SST-treated groups, especially the medium and low dose ones, exhibited significantly improved indices of liver function, including alanine minotransferase （ALT）, aspartate aminotransferase （AST）, albumin （ALB）, total bilirubin （TBIL） and alkaline phosphatase （ALP）. Markedly lowered expression of serum HA, LM and tissular collagen types I, III were also detected radioimmunologically and immunohistochemically in the low dose SST-treated model group. Moreover, pathological findings, such as lessened fibrous septa, decreased hepatic stellate cells （HSCs）, alleviated hepatic steatosis and attenuated inflammation, confirmed the significant improvement in fibrotic degree under the treatment of low dose rather than other doses of SST.Conclusion SST exerts the negative modulatory effect on hepatic fibrosis with a pathophysiological basis of extracellular matrixes （ECM） decreasing and hepatocyte protection. Low dose of SST （50 μg·kg-1·d-1） may be the optimum one among all doses.

Effects of somatostatin on activated rat hepatic stellate cells and its mechanisms

Antiproliferative and Proapoptotic Effects of Somatostatin on Activated Hepatic Stellate Cells.

The Effect of Somatostatin Analogue on Expression of Connective Tissue Growth Factor Gene of Rat Hepatic Stellate Cells

Protective Effects of Somatostatin and Octreotide on Hepatocytes

NEGATIVE REGULATORY EFFECT OF SOMATOSTATIN ON EXPERIMENTAL RAT HEPATIC FIBROSIS

Expression of Subtypes of Somatostatin Receptors in Hepatic Stellate Cells

Relationship Between Somatostatin Receptors and Activation of Hepatic Stellate Cells

NEGATIVE REGULATORY ROLE OF SOMATOSTATIN AND OCTREOTIDE IN EXTRACELLULAR MATRIXES METABOLISM OF RAT HEPATIC STELLATE CELL

EFFECT OF SOMATOSTATIN ON THE CELL CYCLE OF HUMAN GALLBLADDER CANCER CELL

Octreotide modulates the effects on fibrosis of TNF-α, TGF-β and PDGF in activated rat hepatic stellate cells

Effect of Somatostatin on the Gallbladder Cancer Cell Line

Influence of Exogenous Somatostatin on Pancreatic Blood Flow in Normal Rats or Rats with Acute Necrotizing Pancreatitis

Attenuation of Acute Phase Shear Stress by Somatostatin Improves Small-for-size Liver Graft Survival.

Different Effects of Rat Interferon Alpha, Beta and Gamma on Rat Hepatic Stellate Cell Proliferation and Activation.

Anti-carcinoma Effect of Targeted Radiotherapy Using 90Y-Dota-octreotide Mediated by Somatostatin Receptor

Octreotide Inhibits Proliferation and Extracellular Matrix Synthesis in Hepatic Stellate Cells

Influence of somatostatin analogue on human hepatocellular cancer cell line MHCC97-H

Inhibition of Human Pancreatic Cancer Growth by Stilamin in vitro and in vivo

The differential expression of somatostastin receptors in hepatocellular carcinoma HCCLM3 cell lines

Effect of interfering RNA targeting β-Catenin on the proliferation and apoptosis of hepatic stellate cells in vitro

The Apoptosis of Human Hepatocellular Carcinoma Cells Mediated by Somatostatin Receptor Subtypes